NCT04566003 - Evaluation Comparing Tau PET Radiotracers, [18F]GTP1 and [18F]PI-2620 or [18F]MK-6240 in Subjects With Normal Cognition or Prodromal to Moderate Alzheimer's Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 26, 2020

Primary Completion Date

June 27, 2023

Study Completion Date

June 27, 2023

Conditions

Alzheimer Disease (AD)

Interventions

DRUG

[18F]GTP1

Participants will receive a bolus IV of approximately 7mCi of \[18F\]GTP1 radiotracer.

DRUG

[18F]PI-2620

Participants will receive a bolus IV of approximately 5mCi of \[18F\]PI-2620 radiotracer.

DRUG

[18F]MK-6240

Participants will receive a bolus IV of approximately 5mCi of \[18F\]MK-6240 radiotracer.

Trial Locations (1)

Invicro, a Konica Minolta company, New Haven